Circulating Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic Melanoma.

ABSTRACT:

Purpose

Adoptive transfer of activated autologous tumor-infiltrating lymphocytes (TIL) can mediate complete, durable regressions in patients with metastatic melanoma. Responding patients generally do not have significant changes in noncutaneous RECIST targets before 30 to 60 days following TIL infusion, and complete responses are often not confirmed for 1 to 2 years. There is a critical need for a biomarker that can provide early information regarding the likelihood and duration of a response to enable rational decisions about altering therapy. We wished to evaluate the role of circulating tumor DNA (ctDNA) in separating responding from nonresponding patients.

Experimental design

We studied BRAF V600E ctDNA levels by a sensitive allele-specific PCR assay in 388 serum samples

SUBMITTER: Xi L 

PROVIDER: S-EPMC7802600 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature